Antihyperlipidemic drugs are medications designed to lower abnormal levels of fats in the blood, primarily LDL cholesterol (“bad cholesterol”) and triglycerides, and in some cases to raise HDL cholesterol (“good cholesterol”). They span at least half a dozen distinct drug classes, each working through a different mechanism, and collectively they rank among the most widely prescribed medications in the world. Statins dominate the landscape, but newer injectable therapies, combination strategies, and genetic testing are reshaping how clinicians choose and adjust these treatments.
Why Lowering LDL Cholesterol Matters
The link between LDL cholesterol and heart disease is one of the most thoroughly documented relationships in medicine. A large analysis pooling data from over 300,000 participants across 49 studies found that nearly every type of lipid-lowering therapy produced a consistent 20 to 25 percent proportional reduction in major cardiovascular events for each millimole-per-litre drop in LDL cholesterol.1Oxford University Press (European Heart Journal). Low-density lipoproteins cause atherosclerotic cardiovascular disease: 1. Evidence from genetic, epidemiologic, and clinical studies That relationship held regardless of whether LDL was lowered by a statin, a non-statin drug, or a different approach entirely. The practical takeaway is straightforward: the benefit tracks with how far LDL falls, not with which specific pill causes the drop.
Statins
Statins are the first-line treatment for high LDL cholesterol and the drug class with the largest body of outcome evidence. They work by blocking an enzyme in the liver called HMG-CoA reductase, which is a key step in cholesterol production. When the liver makes less cholesterol on its own, it compensates by pulling more LDL out of the bloodstream through increased surface receptors.2PubMed Central. Pleiotropic Effects of Statins on the Cardiovascular System The result is a meaningful drop in circulating LDL levels, typically somewhere between 30 and 50 percent depending on the specific statin and the dose.
The first statin, mevastatin, was isolated from a mold (Penicillium citrinum) in the early 1970s by Japanese biochemist Akira Endo, who was specifically hunting for natural compounds that would block cholesterol production.3International Congress Series. The origin of the statins That discovery set off a wave of analogs. Today, commonly prescribed statins include atorvastatin, rosuvastatin, simvastatin, and pravastatin, each with slightly different potency and drug-interaction profiles. Research also suggests that statins suppress endogenous cholesterol synthesis while simultaneously promoting LDL uptake, a dual effect that is dose-dependent.4PubMed Central. Atorvastatin enhances LDL receptor-mediated LDL-C uptake and modulates PCSK9 protein expression in pancreatic β-cells
Statin Side Effects
Most people tolerate statins without problems, but the side effects that do occur tend to draw a lot of attention. The most common complaint is muscle aches. One proposed mechanism involves coenzyme Q10 (CoQ10), a molecule involved in energy production within cells. Statins interfere with CoQ10 synthesis because it shares part of the same biochemical pathway as cholesterol. Lower CoQ10 levels in blood have been documented in statin users, and some researchers have found reductions in muscle tissue as well, suggesting this deficiency could contribute to muscle symptoms.5PubMed Central. Coenzyme q10 and statin-induced mitochondrial dysfunction The picture is not entirely settled, however. One study measuring CoQ10 directly in muscle biopsies of statin users found that muscle CoQ10 concentrations were comparable between those with muscle pain and those without, even though mitochondrial respiration was lower in the symptomatic group.6The Journal of Clinical Endocrinology & Metabolism. Statin Treatment Decreases Mitochondrial Respiration But Muscle Coenzyme Q10 Levels Are Unaltered: The LIFESTAT Study So the CoQ10 depletion story may be only part of what is happening.
A second concern is the modest increase in new-onset diabetes associated with statin use. The risk appears to be dose-dependent and is most pronounced in people who already have prediabetes, obesity, or other metabolic risk factors.7PubMed Central. Statin Induced New-onset Diabetes Mellitus – A Narrative Review Multiple clinical trials and meta-analyses have confirmed the association, and it appears to be a class effect rather than something limited to one particular statin.8PubMed. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance For most patients at high cardiovascular risk, the heart-disease benefits far outweigh the diabetes risk, but it is something clinicians monitor, especially in borderline cases.
Ezetimibe
Ezetimibe takes a completely different approach from statins. Instead of blocking cholesterol production, it blocks cholesterol absorption in the small intestine. Its target is a transport protein called NPC1L1, located on the brush border of cells lining the upper intestine. By preventing dietary and biliary cholesterol from crossing into the bloodstream, ezetimibe produces a further drop in LDL that complements what a statin achieves.9PubMed Central. Ezetimibe therapy: mechanism of action and clinical update It is generally well tolerated with few side effects and is often added when a statin alone does not get LDL low enough. A fixed-dose combination pill containing both ezetimibe and a statin has been available for years, which simplifies the regimen.
PCSK9 Inhibitors
PCSK9 inhibitors are injectable medications that represent one of the biggest leaps in lipid-lowering therapy in the past decade. PCSK9 is a protein that breaks down LDL receptors on the liver’s surface. By blocking PCSK9, these drugs keep more receptors active, which means the liver clears more LDL from the blood. The two approved monoclonal antibodies, evolocumab and alirocumab, are given by injection every two to four weeks and are used primarily in patients at high or very high cardiovascular risk who have not reached their LDL goals on statins and ezetimibe.10PubMed. Optimizing PCSK9 inhibitor therapy: Understanding and managing suboptimal LDL-C response in clinical practice
A newer PCSK9-targeting therapy, inclisiran, uses a different technology: rather than a monoclonal antibody, it is a small interfering RNA that silences the gene for PCSK9 inside liver cells. It requires only two injections per year after the initial doses, which makes the treatment schedule far lighter. All PCSK9-targeting therapies can cut LDL by roughly 50 to 60 percent on top of background statin treatment.
Bempedoic Acid
Bempedoic acid is a relative newcomer that acts upstream of statins in the same cholesterol-production pathway. It inhibits an enzyme called ATP-citrate lyase (ACL), which sits a step earlier in the chain, and the resulting effect on the liver is similar: LDL receptors increase and more LDL is pulled from the bloodstream.11Nature Communications. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis What makes bempedoic acid interesting is that it is a prodrug activated by an enzyme found mainly in the liver and not in skeletal muscle. That distinction provides a mechanistic basis for why it may avoid the muscle-related side effects that plague some statin users.11Nature Communications. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis It is often prescribed alongside ezetimibe, and a combination pill is available.
Fibrates
While statins and the drugs above focus on LDL, fibrates target a different problem: high triglycerides. They work by activating a transcription factor in the cell nucleus called PPAR-alpha, which orchestrates a cascade of effects in the liver. Fibrates boost the activity of lipoprotein lipase (an enzyme that breaks down triglyceride-rich particles), reduce the liver’s production of a protein called apoC-III that normally slows triglyceride clearance, and enhance the breakdown of fatty acids.12PubMed. Mechanism of action of fibrates on lipid and lipoprotein metabolism The net result is a substantial drop in triglycerides, a moderate decrease in LDL, and usually a rise in HDL.13PubMed Central. Hypertriglyceridemia Therapy: Past, Present and Future Perspectives Common fibrates include fenofibrate and gemfibrozil. Fenofibrate is more commonly used alongside statins because gemfibrozil interacts with statin metabolism in a way that increases the risk of muscle damage.
Bile Acid Sequestrants
Bile acid sequestrants are among the oldest lipid-lowering drugs still in use. They work in the gut, binding to bile acids and preventing their reabsorption. Since the liver needs bile acids for digestion and makes them from cholesterol, this forces the liver to pull more cholesterol out of the blood to replace what was lost, lowering LDL as a consequence. The three main agents are cholestyramine, colestipol, and colesevelam.
These drugs are effective but often hard to tolerate. A large pharmacovigilance study using the FDA’s adverse event reporting system found that all three are prominently associated with gastrointestinal complaints. Cholestyramine stood out for throat irritation, colestipol for swallowing difficulties, and colesevelam for muscle-related symptoms like pain and spasms.14PubMed Central. Update of safety profile of bile acid sequestrants: A real-world pharmacovigilance study of the FDA adverse event reporting system They can also raise triglycerides, so they are generally avoided in people whose triglycerides are already elevated. Bile acid sequestrants have largely been displaced by newer drugs, though they retain a niche for patients who cannot tolerate other classes or need an add-on therapy.
Niacin
Niacin (vitamin B3) is one of the few drugs that improves nearly every lipid parameter: it lowers LDL and triglycerides while raising HDL. Its mechanisms are varied. In the liver, it inhibits triglyceride synthesis and slows the breakdown of HDL particles, allowing HDL levels to rise.15PubMed. Niacin: an old drug rejuvenated It also appears to have anti-inflammatory effects on arterial walls.
Niacin’s biggest practical problem is flushing, a warm, red, sometimes itchy sensation across the face and upper body that occurs shortly after a dose. The flush happens because niacin activates a receptor called GPR109A on skin immune cells, triggering the release of prostaglandin D2, which causes blood vessels in the skin to dilate.16PubMed. Niacin-induced flushing: Mechanism, pathophysiology, and future perspectives Extended-release formulations and taking the dose at bedtime with aspirin can reduce the severity, but many patients still find it intolerable. Combined with trial data that raised questions about whether adding niacin to statin therapy actually improves cardiovascular outcomes, niacin has fallen out of routine use in most guidelines.
Prescription Omega-3 Fatty Acids
Prescription-strength omega-3 fatty acid preparations, particularly icosapent ethyl (purified EPA), are used to treat very high triglycerides. At pharmacological doses, they reduce triglyceride production in the liver and accelerate the clearance of triglyceride-rich particles from the blood. A head-to-head trial comparing EPA alone to a combined EPA-plus-DHA formulation in cardiac surgery patients with high triglycerides found that the combination group achieved lower triglyceride levels and reduced markers of oxidative stress, though poor medication compliance in the EPA-only group complicated interpretation.17Circulation Journal. Long-Term Comparison of Ethyl Icosapentate vs. Omega-3-Acid Ethyl in Patients With Cardiovascular Disease and Hypertriglyceridemia (DEFAT Trial) The REDUCE-IT trial, which tested high-dose icosapent ethyl against placebo in statin-treated patients with elevated triglycerides, showed a significant reduction in cardiovascular events and pushed icosapent ethyl into guideline recommendations.
Emerging Therapies
For patients with severe genetic forms of high cholesterol, particularly homozygous familial hypercholesterolemia (HoFH), even the combination of a statin, ezetimibe, and a PCSK9 inhibitor may not bring LDL to safe levels. Evinacumab is a monoclonal antibody that targets a different protein, ANGPTL3, which normally inhibits enzymes responsible for breaking down triglyceride-rich lipoproteins.18PubMed Central. Evinacumab: Mechanism of action, clinical, and translational science In clinical trials, a monthly intravenous infusion of evinacumab reduced LDL by about 50 percent in HoFH patients, including those who respond poorly to other treatments because their LDL receptors are non-functional.19PubMed. Evinacumab for Homozygous Familial Hypercholesterolemia Other emerging approaches include RNA-based therapies targeting lipoprotein(a), a genetically determined risk factor that existing drugs largely do not address.
What Happens When You Cannot Tolerate Statins
Statin intolerance, usually defined as muscle symptoms bad enough to cause a patient to stop the drug, is commonly reported. But what “intolerance” means in practice is less straightforward than it sounds. A large retrospective analysis at the Cleveland Clinic found that about 73 percent of patients labeled as statin-intolerant were able to tolerate a statin again over roughly two and a half years of follow-up, often by switching to a different statin or using an intermittent dosing schedule.20PubMed Central. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience Patients on intermittent dosing (say, every other day or a few times a week) achieved a smaller LDL reduction than daily users but still did meaningfully better than those who stopped entirely.
For people who truly cannot take any statin at any dose, the non-statin options described above become the backbone of treatment. Bempedoic acid is often a first substitute because it works in a statin-like pathway without the muscle exposure. Ezetimibe, PCSK9 inhibitors, and bile acid sequestrants can all be layered on top. The key point is that abandoning lipid treatment altogether because of statin intolerance is rarely necessary.
Genetics and Drug Response
Not everyone responds to these drugs the same way, and genetics plays a measurable role. The best-studied example involves a gene called SLCO1B1, which encodes a transporter protein responsible for moving statins from the blood into the liver. A particular variant of this gene (called the *5 allele, present in roughly 15 percent of the population) impairs that transport, leaving more statin circulating in the blood and exposing muscles to higher concentrations.21PubMed. SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study A genome-wide study found that carrying one copy of this variant roughly quadrupled the odds of developing statin-related muscle damage, and carrying two copies raised the cumulative incidence of muscle problems to about 18 percent within a year of therapy, dramatically higher than in non-carriers.22Genetics in Medicine. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review Pharmacogenomic testing for SLCO1B1 is already available, and some guidelines recommend it before starting high-dose simvastatin in particular. As testing becomes cheaper, it may become routine for a broader range of statins and doses.
Guideline Differences on LDL Targets
If you read European and American guidelines side by side, you will notice they do not always agree on how aggressively to lower LDL. The European guidelines (ESC/EAS) tend to set explicit numerical LDL targets tied to risk categories, with a goal below about 55 mg/dL for very-high-risk patients. The American guidelines (ACC/AHA) have historically set the bar at below 70 mg/dL for the same group and place more weight on shared decision-making, lifetime risk assessment, and additional biomarkers like coronary artery calcium and lipoprotein(a).23PubMed Central. Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI The European approach emphasizes a treat-to-target philosophy with clear escalation steps, while the American approach gives more room for individualized discussion between doctor and patient.24PubMed. Comparison of the 2025 ESC/EAS and 2026 ACC/AHA Guidelines for Dyslipidemia Management Both frameworks agree on the centrality of statins and on the use of add-on therapies when statins alone are not enough. The practical effect is that a European clinician may escalate to a PCSK9 inhibitor sooner than an American counterpart would for the same patient.
Monitoring While on Treatment
Before starting any lipid-lowering drug, your doctor will typically check a fasting lipid panel along with liver enzymes and creatine kinase (a marker for muscle damage) to establish baseline values. Once treatment is underway and stable, guidelines do not require routine enzyme monitoring in the absence of symptoms.25PubMed Central. Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy The focus shifts to watching for clinical symptoms: unexplained muscle pain, weakness, dark urine (which could signal severe muscle breakdown), or signs of liver trouble like jaundice. A randomized controlled study comparing statin monotherapy to combination therapy found that while liver enzymes rose modestly in both groups over 24 weeks, mean values stayed well below thresholds considered clinically significant.26Future Journal of Pharmaceutical Sciences. Evaluation of relative safety and therapeutic efficacy of antihyperlipidemic drug regimens used alone or in combination in cardiovascular disease: randomized controlled study Lipid levels themselves are rechecked about 6 to 12 weeks after starting or adjusting a medication, and periodically thereafter to confirm the drug is still working and to guide any need for dose changes or additional therapy.
Children and Familial Hypercholesterolemia
Most conversations about cholesterol-lowering drugs focus on middle-aged and older adults, but children with familial hypercholesterolemia (FH) are an important exception. FH is a genetic condition that causes dangerously high LDL from birth, and without treatment, affected individuals face premature heart disease, sometimes in their twenties or thirties. A landmark 20-year follow-up study found that starting statin therapy during childhood in FH patients slowed the thickening of carotid artery walls and reduced the risk of cardiovascular disease in adulthood.27PubMed. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia A Cochrane review covering multiple trials in children with FH concluded that statins lowered LDL at every time point examined, with little difference in liver enzymes, creatine kinase, or clinical adverse events compared to placebo.28PubMed Central. Statins for children with familial hypercholesterolemia PCSK9 inhibitors are also being studied in pediatric FH patients, with trials like HAUSER-RCT evaluating evolocumab as add-on therapy in children and adolescents.29PubMed. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study
The Cost Question
Generic statins cost pennies per day, which is one reason they have been so widely prescribed. But the newer therapies raise much thornier questions about value. PCSK9 inhibitors initially launched at annual list prices above $14,000 in the United States, and although prices have come down, cost-effectiveness analyses in multiple countries still struggle to show they are a good deal for the healthcare system at large. A UK-based analysis estimated that evolocumab and alirocumab added about half a quality-adjusted life year (QALY) at a cost that exceeded what the National Health Service considers acceptable per QALY gained.30PubMed Central. PCSK9 inhibition: from effectiveness to cost-effectiveness A broader cost-effectiveness comparison found that, in secondary prevention, icosapent ethyl and ezetimibe were cost-effective or even cost-saving when added to statins, while PCSK9 inhibitors had zero probability of being cost-effective at a willingness-to-pay threshold of £25,000 per QALY.31PubMed Central. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
In developing countries the picture is mixed. Evolocumab showed favorable cost-effectiveness in some settings, like when added to statins after an acute heart attack in certain middle-income nations, but was not cost-effective in others. Alirocumab and inclisiran generally fared worse on the cost ledger in low-resource settings.32PubMed Central. Fair pricing, fair access; a systematic review of cost-effectiveness of new hyperlipidemia injectable medication in developing countries The upshot is that for most patients worldwide, statins and ezetimibe remain the backbone of treatment not only because they work well but because they are affordable. Expensive injectables are reserved for the subset of patients whose risk is high enough and whose LDL is stubborn enough that the extra benefit justifies the price.